Seventeen patients with recurrent prostate cancer received continuous low-dose subcutaneous IL-2 (1.2 × 106 IU/m2/day) daily for 8 weeks with weekly intravenous infusions of J591 (25 mg/m2) during weeks 4–6. The gene discussed is IL2; the disease is Familial prostate cancer.